Making improved earnings power the top priority
First written in FY2016-Q2. 25 of 39 entries say "Advanced", first in FY2016-Q3. Latest entry: 2026-08-07.
The whole theme swung hardest in 2025: 18 of 111 companies on the "Worse" side.
3 other companies' latest entry also says "Cited as achieved".
- 2026-08-07Cited as achievedRevisions to earnings forecasts
「Six months ended 30 June 2026 1,217,876 7.2 128,303 36.1」
Actual revenue and business profit for the six months ended 30 June 2026 were presented as evidence of improved earnings power. - FY2026-H1AdvancedAnnual report
「Consolidated business profit ¥128.3 billion (up 36.1% year on year)」
Consolidated business profit for the first half of 2026 was ¥128.3 billion, up 36.1% year on year, reflecting a substantial improvement in earning power driven by lower costs and higher gross profit. - 2026-05-14AdvancedEarnings
「Three months ended 31 March 2026 573,033 5.0 49,992 37.7」
Revenue for the first quarter increased 5.0% year on year, while business profit rose 37.7%, demonstrating an improvement in earnings power. - FY2025AdvancedAnnual report
「Existing alcoholic beverages, beverages and pharmaceuticals businesses also performed steadily. As a result of delivering results above plan, consolidated business profit reached a record high for the third consecutive year.」
Consolidated business profit in 2025 was ¥251.8 billion, up 19.3% year on year, marking a record high for the third consecutive year. - FY2025-H1AdvancedAnnual report
「Consolidated business profit increased overall due to the contribution from ファンケル from the beginning of the year and higher profit in the health science business, including 協和発酵バイオ.」
Consolidated business profit was ¥94.2 billion, up 1.3% year on year, supported by ファンケル's contribution from the beginning of the year and higher profit in the health science business. - FY2024AdvancedAnnual report
「In line with the Kirin Group 2022–2024 Medium-Term Management Plan, we generated results through expanded business profit in the alcoholic beverages and beverages businesses, a strengthened global foundation for the pharmaceuticals business, and the expansion of the health science business, achieving record-high consolidated business profit, the profit metric used to measure the continuing performance of the businesses.」
Consolidated business profit in 2024 was ¥211.0 billion, up 4.7% year on year, achieving a record high. Higher profit in the alcoholic beverages, beverages and health science businesses more than offset lower profit in pharmaceuticals. - FY2024-H1AdvancedAnnual report
「Consolidated business profit ¥93.1 billion (up 23.8% year on year)」
Consolidated business profit for the first half was ¥93.1 billion, up 23.8% year on year. Price revisions, higher profit at Coca-Cola Beverages Northeast, Inc. and growth in global strategic products improved overall earning power. - FY2024-Q1WorsenedAnnual report
「Consolidated business profit ¥33.1 billion (down 1.5% year on year)」
Although consolidated revenue increased 11.4% year on year, consolidated business profit declined to ¥33.1 billion, down 1.5%, due to lower profit in the alcoholic beverages business and other businesses where investment in brand development was strengthened. - FY2023AdvancedAnnual report
「Consolidated business profit declined at キリンビバレッジ㈱ and 協和発酵バイオ㈱, among others, but increased in the domestic beer and spirits, Oceania alcoholic beverages and pharmaceuticals businesses and at コーク・ノースイースト社, resulting in an overall increase.」
Consolidated business profit in 2023 was ¥201.5 billion, up 5.4% year on year, as profit growth in other businesses more than offset declines in the domestic beverages business and elsewhere. - FY2023-Q3AdvancedAnnual report
「Consolidated business profit ¥141.5 billion (up 4.7% year on year) (Reference) Normalized EPS ※ ¥134 (up 9.8% year on year)」
Cumulative consolidated business profit for the third quarter was ¥141.5 billion, up 4.7% year on year, and normalized EPS was ¥134, up 9.8%. Profit attributable to owners of the parent declined due to a loss on the transfer of shares in ミャンマー・ブルワリー社 and other factors, but recurring earning power improved. - FY2023-Q2AdvancedAnnual report
「Business profit declined in the Oceania alcoholic beverages business, where investment in brand development was strengthened, and in the pharmaceuticals business, where expenses including research and development costs increased. However, profit in the domestic beer and spirits business, where the effects of price revisions implemented in the prior year emerged as expected, and at コーク・ノースイースト社, where sales were strong, exceeded the prior-year level, resulting in an overall increase in profit.」
Consolidated business profit in the first half of 2023 was ¥75.2 billion, up 4.3% year on year, as higher profit in the domestic beer and spirits business and at コーク・ノースイースト社 more than offset lower profit in the Oceania alcoholic beverages and pharmaceuticals businesses. Normalized EPS was ¥73, up 14.1%. - FY2023-Q1AdvancedAnnual report
「Consolidated business profit ¥33.6 billion (up 29.5% year on year)」
Consolidated business profit was ¥33.6 billion, up 29.5% year on year, indicating an improvement in Group-wide earning power. - FY2022AdvancedAnnual report
「While building a strong brand portfolio through activities focused on core brands, the Group worked to expand products and services offering new value propositions. In response to surging raw-material and fuel prices, each operating company worked to improve profitability through productivity gains and product price revisions.」
Consolidated business profit in 2022 was ¥191.2 billion, up 15.6% year on year. The Group improved earning power by focusing on core brands, increasing productivity and revising prices. - FY2022-Q3AdvancedAnnual report
「Consolidated business profit ¥135.2 billion (up 14.5% year on year) (Reference) Normalized EPS ※ ¥122 (up 15.1% year on year)」
Cumulative consolidated business profit for the third quarter was ¥135.2 billion, up 14.5% year on year, while normalized EPS was ¥122, up 15.1%, indicating an improvement in earning power from the prior-year period. - FY2022-Q2AdvancedAnnual report
「Consolidated business profit ¥72.1 billion (up 0.2% year on year)」
Consolidated business profit was ¥72.1 billion, up 0.2% year on year. Although profit declined in the domestic beer and spirits, domestic beverages and Oceania alcoholic beverages businesses, higher profit in pharmaceuticals kept the overall result broadly in line with the prior year. - FY2022-Q1WorsenedAnnual report
「Consolidated business profit declined overall because profit in the domestic beer and spirits business, where competition intensified, and the Oceania alcoholic beverages business, which was heavily affected by COVID-19, fell below the prior-year level. Consolidated business profit ¥25.9 billion (down 21.8% year on year)」
Lower profit in the domestic beer and spirits and Oceania alcoholic beverages businesses reduced consolidated business profit to ¥25.9 billion, down 21.8% year on year, weighing on earning power. - FY2021AdvancedAnnual report
「Consolidated business profit declined in the domestic beer and spirits business and at ミャンマー・ブルワリー社, among others, but increased in the Oceania alcoholic beverages business, 協和発酵バイオ㈱ and コーク・ノースイースト社, resulting in an overall increase.」
Consolidated business profit was ¥165.4 billion, up 2.0% year on year, indicating an improvement in overall earning power despite lower profit in the domestic beer business and elsewhere. - FY2021-Q3WorsenedAnnual report
「Consolidated business profit declined year on year overall because, although profit increased in the Oceania alcoholic beverages business, profit in the domestic beer and spirits, domestic beverages and pharmaceuticals businesses fell below the prior-year level. Consolidated business profit ¥118.0 billion (down 9.4% year on year)」
Although profit increased in the Oceania alcoholic beverages business, lower profit in the domestic beer and spirits, domestic beverages and pharmaceuticals businesses reduced consolidated business profit to ¥118.0 billion, down 9.4% year on year. - FY2021-Q2AdvancedAnnual report
「Consolidated business profit ¥71.9 billion (up 2.9% year on year)」
Cumulative consolidated business profit for the second quarter was ¥71.9 billion, up 2.9% year on year, indicating an improvement in Group-wide earning power. - FY2021-Q1AdvancedAnnual report
「Consolidated business profit ¥33.1 billion (up 1.1% year on year)」
Consolidated business profit was ¥33.1 billion, up 1.1% year on year, due to higher profit in the domestic beer and spirits and Oceania alcoholic beverages businesses, which had been significantly affected by COVID-19 in the prior year. Quarterly profit attributable to owners of the parent declined 16.3%, while normalized EPS declined 6.9%. - FY2020WorsenedAnnual report
「2020 actual 2019 actual Year-on-year change Year-on-year change rate Consolidated business profit ¥162.1 billion ¥190.8 billion Down ¥28.6 billion Down 15.0%」
Consolidated business profit in fiscal 2020 was ¥162.1 billion, down 15.0% year on year, confirming the deterioration in earning power in the full-year results. - FY2020-Q3WorsenedAnnual report
「Consolidated business profit ¥130.3 billion (down 12.2% year on year)」
Due to the spread of COVID-19, most segments other than pharmaceuticals reported lower profit. Consolidated business profit fell 12.2% year on year, while normalized EPS declined 8.6% to ¥106. - FY2020-Q2WorsenedAnnual report
「Consolidated revenue ¥872.5 billion (down 6.2% year on year) Consolidated business profit ¥69.9 billion (down 23.1% year on year)」
Due to the spread of COVID-19, most segments other than pharmaceuticals reported lower revenue and profit. Consolidated business profit was ¥69.9 billion, down 23.1% year on year. - FY2020-Q1WorsenedAnnual report
「Consolidated business profit ¥32.8 billion (down 11.0% year on year)」
Consolidated business profit was ¥32.8 billion, down 11.0% year on year, as lower profit in the domestic beer and spirits, Oceania integrated beverages and pharmaceuticals businesses weighed on earning power. - FY2019WorsenedAnnual report
「Consolidated business profit ¥190.8 billion ¥199.3 billion Down ¥8.6 billion Down 4.3%」
Consolidated business profit in 2019 was ¥190.8 billion, down ¥8.6 billion, or 4.3%, from the prior year. Profit growth in existing businesses and the pharmaceuticals business was offset by lower profit in the Oceania integrated beverages business and other factors, resulting in lower Group-wide profit. - FY2019-Q3AdvancedAnnual report
「Consolidated business profit ¥148.4 billion (up 0.8% year on year) (Reference) Normalized EPS ※ ¥116 (down 4.9% year on year)」
Consolidated business profit was ¥148.4 billion, up 0.8% year on year, while normalized EPS was ¥116, down 4.9% year on year. - FY2019-Q2AdvancedAnnual report
「Consolidated business profit ¥90.8 billion (up 5.0% year on year)」
Cumulative consolidated business profit for the second quarter was ¥90.8 billion, up 5.0% year on year, demonstrating measurable improvement in earning power. Quarterly loss attributable to owners of the parent was ¥7.3 billion due to impairment losses and other factors. - FY2019-Q1WorsenedAnnual report
「Consolidated business profit was broadly in line with the prior-year level, as lower profit in the domestic beverages and Oceania integrated beverages businesses was offset by support from the domestic beer and spirits and pharmaceuticals and biochemical businesses.」
Consolidated business profit was ¥36.9 billion, down 0.6% year on year, as lower profit in the domestic beverages and Oceania integrated beverages businesses weighed on earning power. - FY2018AdvancedAnnual report
「Business profit declined in both the Oceania integrated beverages and pharmaceuticals and biochemical businesses due to foreign exchange effects in Oceania and the exclusion of 協和メデックス㈱ from consolidation, among other factors. However, a substantial increase in profit in the Japan Integrated Beverages business, supported by strong performance at キリンビール㈱, resulted in record-high business profit.」
Despite profit declines in some businesses, consolidated business profit reached a record ¥199.3 billion, up 2.4% year on year, supported by キリンビール㈱. - FY2018-Q3WorsenedAnnual report
「Business profit declined due to lower profit in the Oceania integrated beverages business, reflecting foreign exchange effects and lower sales volumes, and lower profit in the pharmaceuticals and biochemical businesses due to drug price reductions and other factors. Consolidated business profit ¥147.2 billion (down 1.1% year on year)」
Consolidated business profit was ¥147.2 billion, down 1.1% year on year, as lower profit in the Oceania integrated beverages and pharmaceuticals and biochemical businesses weighed on earning power. - FY2018-Q2WorsenedAnnual report
「Business profit declined due to lower profit in the Oceania integrated beverages business, reflecting a stronger yen and weaker Australian dollar than in the prior-year period, and lower profit in the pharmaceuticals and biochemical businesses, which were affected by drug price reductions and other factors.」
Consolidated business profit was ¥86.1 billion, down 4.3% year on year, as lower profit in the Oceania integrated beverages and pharmaceuticals and biochemical businesses weighed on earning power. - FY2018-Q1WorsenedAnnual report
「As a result, in the first quarter of the current consolidated fiscal year, consolidated revenue increased due to higher revenue in the Japan Integrated Beverages and overseas integrated beverages businesses, driven by higher sales volumes at キリンビール㈱. Consolidated business profit, however, decreased due in part to lower revenue and profit in the pharmaceuticals and biochemical businesses. Consolidated business profit ¥36.9 billion (down 3.8% year on year)」
Although revenue increased, consolidated business profit declined to ¥36.9 billion, down 3.8% year on year, due in part to lower revenue and profit in the pharmaceuticals and biochemical businesses, weighing on Group-wide earning power. - FY2017AdvancedAnnual report
「During the current fiscal year, the Group achieved particularly strong results in revitalizing and restructuring low-profit businesses, one of the priority issues under the 2016 Medium-Term Plan. As each operating company progressed smoothly against plan, led by a substantial increase in profit at キリンビバレッジ㈱, business profit reached a record high. Consolidated business profit ¥194.3 billion (up 6.8% year on year)」
Revitalization and restructuring of low-profit businesses advanced further, and consolidated business profit reached a record high of ¥194.3 billion, up 6.8% year on year. - FY2017-Q3AdvancedAnnual report
「Consolidated operating profit increased as a result of higher profit in the Japan Integrated Beverages business and the pharmaceuticals and biochemical businesses. Consolidated ordinary profit also increased, supported by the contribution from equity-method investment profit. Consolidated operating profit ¥128.0 billion (up 15.7% year on year)」
Cumulative consolidated operating profit for the third quarter was ¥128.0 billion, up 15.7% year on year, demonstrating measurable improvement in earning power. - FY2017-Q2AdvancedAnnual report
「Consolidated operating profit increased substantially year on year, driven by higher profit in the Japan Integrated Beverages business and the pharmaceuticals and biochemical businesses. Consolidated ordinary profit also increased.」
Cumulative consolidated operating profit for the second quarter was ¥79.7 billion, up 35.7% year on year, demonstrating measurable improvement in earning power. - FY2017-Q1AdvancedAnnual report
「Consolidated operating profit ¥36.8 billion (up 45.4% year on year)」
First-quarter consolidated operating profit was ¥36.8 billion, up 45.4% year on year, demonstrating measurable improvement in earning power. - FY2016AdvancedAnnual report
「As a result, during the current consolidated fiscal year, revitalization and restructuring of low-profit businesses, one of the priority issues, progressed ahead of plan, led by the recovery of キリンビバレッジ㈱ and ブラジルキリン社. Breakthrough growth in the pharmaceuticals and biochemical businesses progressed as planned.」
Under the plan prioritizing improved earning power, low-profit businesses progressed ahead of plan, while the pharmaceuticals and biochemical businesses progressed as planned. Consolidated operating profit was ¥141.8 billion, up 13.7% year on year. - FY2016-Q3AdvancedAnnual report
「Under the 2016 Medium-Term Plan, improving earning power was made the top priority. The Group began initiatives to strengthen the competitiveness of existing businesses through investment with clear priorities and fundamentally reform the earnings structure of low-profit businesses.」
The top priority and related measures were reiterated. Consolidated operating profit for the cumulative third quarter was ¥110.6 billion, up 8.2% year on year. - FY2016-Q2First statedAnnual report
「Under the 2016 Medium-Term Plan, improving earning power was made the top priority. The Group began initiatives to strengthen the competitiveness of existing businesses through investment with clear priorities and fundamentally reform the earnings structure of low-profit businesses.」
Improving earning power was positioned as the plan's top priority, with investment and structural reform identified as the means of achieving it.